Active substance
Aceclofenac
- SFDA 2
- NHS prices 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| GLADIO | 100 mg | Film-coated tablet · Oral use | 20 Bottle | SAR 17.30 | Generic · Prescription | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Valid |
| AIRTAL 100 MG F- C TABLETS | 100 mg | Film-coated tablet · Oral use | 20 Blister | SAR 20.35 | NCE · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS-PAIN MANAGEMENT; ANKYLOSING SPONDYLITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; CHRONIC PANCREATITIS; DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; EPIDERMOLYSIS BULLOSA; LOW BACK PAIN; MENSTRUAL DISORDERS; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; NON-INFECTIOUS UVEITIS; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS; SICKLE CELL DISEASE - PAIN MANAGEMENT
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Aceclofenac 100mg tablets | £9.50 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- MHRA 22 Jan 2015 Aceclofenac (Preservex): updated cardiovascular advice in line with diclofenac and COX-2 inhibitors
Aceclofenac is now contraindicated in patients with certain established cardiovascular diseases.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.